JP Morgan 2025: AbbVie counts on Skyrizi and Rinvoq to fill Humira-sized hole
AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira sales drop.
AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira sales drop.
What's Your Reaction?
